Long-Acting GLP-1 Receptor Agonism Ameliorates Sinoatrial Node Dysfunction by Attenuating Electrophysiological and Structural Remodeling
Year: 2026
Type: preprint
Abstract: Background Sinoatrial node dysfunction (SND) causes bradyarrhythmia, while pacemaker therapy does not reverse injury to the sinoatrial node (SAN). Long-acting GLP-1 receptor agonists (GLP-1RAs) raise heart rate, but whether they can repair an injured SAN in SND remains unknown. Methods In streptozotocin-induced SND rats, we studied an acute phase (SND, GLP-1RA treatment, glycemic control, and GLP-1R antagonist groups) and a chronic phase (SND, GLP-1RA treatment, and glycemic control groups). Endpoints included heart rate, RR interval, heart rate variability, intrinsic heart rate (IHR), corrected sinus node recovery time after adenosine injection (ADSNRT), SAN transcriptomics, histology and immunofluorescence, HL-1 cell oxidative-stress studies, and public single-cell data. Results At the acute endpoint, the long-acting GLP-1RA efsubaglutide alfa (eSuba) increased heart rate (372.76 ± 11.06 vs 312.64 ± 22.28 beats/min; P < 0.0001) and IHR (349.45 ± 10.49 vs 234.79 ± 12.29 beats/min; P < 0.0001), and shortened ADSNRT (4.22 ± 2.75 vs 20.68 ± 1.60 s; P = 0.0009); improvements in heart rate (349.05 ± 17.73 vs 266.02 ± 13.52 beats/min; P < 0.0001) and IHR persisted in the chronic phase. SAN transcriptomics showed reversal of extracellular matrix, inflammatory/immune, redox/mitochondrial, glial, and electrical programs. The GLP-1RA reduced collagen deposition and CCR2a + infiltration, decreased ox-CaMKII/CaMKII, increased SIRT3, restored Ca v 1.3, Na v 1.5, SERCA2a and p-RyR2 (Ser2808), and increased p-PKA/PKA. The glycemic control comparator produced limited improvement, and the GLP-1R antagonist attenuated most effects. Conclusions Long-acting GLP-1R agonism improves SAN function in SND via glucose-independent attenuation of electrophysiological and structural remodeling, an effect that is at least partly GLP-1R dependent. Clinical Perspective What is new? In metabolically stressed rats with established SAN dysfunction, a long-acting GLP-1RA improved SAN function by attenuating electrophysiological and structural remodeling rather than merely raising heart rate, and an insulin comparator matched for glycemic control did not reproduce these benefits—uncoupling SAN repair from glucose lowering. Mechanistically, eSuba attenuated SAN oxidative stress and mitochondrial injury (reduced oxidized CaMKII, increased SIRT3) and restored intracellular Ca 2+ cycling (increased Ca v 1.3, SERCA2a, and p-RyR2 [Ser2808]), effects that were blunted by GLP-1R blockade. SND also reactivated a SAN Schwann/glial transcriptional program ( S100b ; Ncmap ; etc.) that eSuba reversed, suggesting a modifiable neuro-glial component beyond pacemaker-cell failure. What are the clinical implications? For patients with SND and metabolic disturbances, GLP-1RAs may have therapeutic potential beyond glucose and weight reduction, providing proof of concept for a pharmacological strategy beyond pacemakers. The heart-rate effects and safety of GLP-1RAs in patients with bradyarrhythmia warrant reassessment; in the setting of SND, a rise in heart rate may represent a therapeutic effect rather than an adverse reaction.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7234081287
